Invesco
TCRR

Invesco’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Invesco’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,419
Closed -$114K – 4125
2021
Q3 		$114K Buy
13,419
+1,199
+10% +$16.9K ﹤0.01% 3917
2021
Q2 		$201K Buy
+12,220
New +$247K ﹤0.01% 3789
2021
Q1 		– Sell
-204,486
Closed -$6.32M – 3971
2020
Q4 		$6.32M Buy
204,486
+159,877
+358% +$4.04M ﹤0.01% 2066
2020
Q3 		$907K Buy
44,609
+3,246
+8% +$57K ﹤0.01% 2864
2020
Q2 		$636K Buy
+41,363
New +$477K ﹤0.01% 3019

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco's TCRR Position: Q4 2021 in Review

Invesco sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 13,419 shares — an estimated $114K sold.

Invesco first reported a position in TCRR in Q2 2020 and held it in 5 quarters. The position peaked at $6.32M in Q4 2020. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

  • Invesco reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Invesco sold 13,419 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $114K.
  • Invesco first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2020 and held it in 5 quarters.
  • Invesco's TCR2 Therapeutics Inc. Common Stock position peaked at $6.32M in Q4 2020.
  • 122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on Invesco's 13F filing for Q4 2021, filed 14 Feb 2022.